文献速递肝病

MASH临床试验与药物研发管线:一场迫在眉睫的海啸

MASH clinical trials and drugs pipeline: An impending tsunami.
PubMed 文献 · Hepatology · 2024-03-19

代谢功能障碍相关脂肪性肝病已成为西方国家主要慢性肝病和肝移植重要原因,MASH可进展为纤维化、肝硬化、肝癌和肝衰竭。2024年有望迎来首个获批药物,多种作用机制(甲状腺激素受体、GLP-1、PPAR等)正在研究中,3期试验主要采用脂肪性肝炎缓解且纤维化不恶化、和/或纤维化改善且脂肪性肝炎不恶化两个主要终点。

要点

  • MASH可进展为纤维化、肝硬化、肝癌和肝衰竭,是肝移植的重要原因。
  • 3期试验主要终点为脂肪性肝炎缓解且纤维化不恶化,和/或纤维化改善且脂肪性肝炎不恶化。
  • 2期试验探索替代无创终点,联合用药试验已在进行中。

核心结论

  • 2024年有望迎来首个获批的MASH药物,多种药物机制和联合治疗正在探索中。

研究设计与样本

  • 综述,讨论截至2023/2024年MASH药物研究的前沿机制、结局和未来方向。

主要发现

  • 已研究甲状腺激素受体、胰高血糖素样肽1、过氧化物酶体增殖物激活受体及影响肝脂肪变合成、炎症通路、遗传因素、纤维化机制的药物。
  • 3期临床试验主要终点为脂肪性肝炎缓解且纤维化不恶化,和/或纤维化改善且脂肪性肝炎不恶化。
  • 2期临床试验探索替代无创终点。
  • 部分联合用药试验已在进行中。

关键数值与推荐

  • 3期试验主要终点:脂肪性肝炎缓解且纤维化不恶化,和/或纤维化改善且脂肪性肝炎不恶化。
  • 2期试验探索替代无创终点。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Metabolic dysfunction-associated steatotic liver disease, formerly known as NAFLD, has ascended to prominence as the predominant chronic liver disease in Western countries and now stands as a leading cause of liver transplantations. In the more advanced stage, metabolic dysfunction-associated steatohepatitis (MASH) may lead to fibrosis, a gateway to cirrhosis, liver cancer, and liver failure. Despite extensive research and exploration of various drug mechanisms, the anticipation for the inaugural approved drug to materialize by 2024 is palpable, marking a significant milestone. Numerous pathways have been investigated for MASH treatment, exploring thyroid hormone receptors, glucagon-like peptides 1, peroxisome proliferator-activated receptors, and agents influencing hepatic steatosis synthesis, inflammatory pathways, genetic components, fibrosis mechanisms, and an array of other avenues. Over time, key regulatory directions have crystallized, now manifesting in 2 primary endpoints under investigation: resolution of steatohepatitis without worsening fibrosis and/or improvement of fibrosis stage without worsening of steatohepatitis, especially used in phase 3 clinical trials, while alternative noninvasive endpoints are explored in phase 2 trials. The prospect of proving efficacy in clinical trials opens doors to combination therapies, evaluating the ideal combination of drugs to yield comprehensive benefits, extending beyond the liver to other organs. Certain combination drug trials are already underway. In this review, we discuss the forefront of MASH drug research as of 2023/2024, illuminating mechanisms, outcomes, and future trajectories. Furthermore, we tackle the challenges confronting MASH trials and propose potential strategies for surmounting them.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Noureddin M. MASH clinical trials and drugs pipeline: An impending tsunami. Hepatology. 2024. PMID: 38502810. doi:10.1097/HEP.0000000000000860

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。